Josep M Llibre
University Hospital, University of Barcelona, Spain
Dr. Josep M Llibre studied Medicine at the Central University of Barcelona (Spain) in the Clinic Hospital, and qualified in 1984. He became involved there in Infectious Diseases since 1982 at the B Medical Clinic. He obtained his specialty in Internal Medicine through the national MIR exam in 1990 in the Autonomous University of Barcelona, at the University Hospital Germans Trias i Pujol (Barcelona). He started caring for patients with HIV/AIDS in 1987. He is a Consultant Physician at the “Lluita contra la SIDA” Foundation, and the HIV Unit in the University Hospital Germans Trias i Pujol, in Badalona, Barcelona, Spain. He has previously worked as HIV consultant physician in the Internal Medicine Dept at the Hospital of Calella, in Barcelona, Spain, where he was the HIV/AIDS Coordinator. His main fields of interest in HIV Medicine include the clinical implications of HIV-1 resistance, HIV-1 antiretroviral treatment clinical trials (both in naïve and pretreated patients), with special interest on drug efficacy, pharmacoeconomics, and basic research in HIV-1 reservoirs and residual viral replication in treated patients with virological suppression. He has published widely on journals and book chapters on clinical aspects of HIV-1 treatment and care, HIV-1 resistance, clinical reviews, positioning papers, and treatment intensification strategies, and participated in many pivotal clinical trials. He has also published in basic science investigation journals like Nature Med, Science, and PLoS Pathogens. He is a member of the Panel of the Spanish Antiretroviral Treatment Guidelines, and Consultant of the Catalan Health Service in antiretroviral treatment, and collaborates on peer reviewing with many top medical journals. He lectures at both international and Spain levels, and is involved in HIV Medical Educational training both in Spain and European Countries.
My research is focused on Clinical Investigation of HIV/AIDS, with special interest in antiretroviral efficacy trials, clinical implications of HIV resistance, HIV salvage treatments, and HIV eradication.